Knuuttila E, et al. - Through a randomized clinical trial where 158 men with prostate cancer were given 80 mg atorvastatin (ATV) or placebo daily for a median of 27 days pre-radical prostatectomy, the experts assessed if anticancer effects of statin were due to systemic cholesterol-lowering or direct local growth inhibition in the prostate and if statins could access the prostate. Between the plasma and tissue concentrations, no statistically significant linear trends were recognized. The concentrations were in balance in the plasma when assessing the relative concentration of atorvastatin lactone vs ATV, but in the prostate, the relative concentration of atorvastatin lactone was 57% lower vs ATV. Further, they could not find any effect modification by tumor or population features. In accessing the prostate from the circulation, measurable ATV concentrations in the prostate supported ATV's ability. Also, compared to the plasma concentration, intraprostatic concentrations remain raised, indicating ATV could collect in the prostate.